Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Genomics Group Reports Second Quarter Revenues of $20.3 Million

Rockville, MD - January 25, 2001

Celera Genomics Group (NYSE: CRA), a business of Applera Corporation, today reported results for its second fiscal quarter ended December 31, 2000. The Group’s revenues for the second quarter increased to $20.3 million compared with $8.3 million in the same period last year. The increase in revenues resulted principally from subscription agreements with commercial and academic customers. The net loss after benefit for taxes was $29.7 million, or $0.49 per share, compared with a net loss of $24.3 million, or $0.47 per share, in last year’s second quarter. Selling, general and administrative expenses increased to $14.4 million, as Celera continued to expand its sales and marketing group and its business development team. Included in this quarter’s results is a non-cash charge of $11.0 million for amortization of intangibles primarily related to the acquisition of Paracel, Inc. in June 2000.

Research and development expenditures were $52.7 million. Celera is beginning to put in place the assets to expand its efforts in the development of its proteomics and functional genomics capabilities. Celera recently appointed Scott Patterson, Ph.D., to lead its efforts in proteomics. Dr. Patterson has extensive scientific experience in protein analysis and its application to understanding biological processes. Celera is also currently increasing its scientific research teams, including the recent appointment of Stephen Hoffman, M.D., who will establish and lead a team designed to create and develop immunotherapeutic products from Celera’s potential new discoveries in its proteomics and functional genomics initiatives.

For the six months ended December 31, 2000, Celera reported revenues of $38.6 million, compared with $16.6 million for the comparable period in fiscal 2000. The net loss during the first six months of fiscal 2001, after benefit for taxes, was $55.4 million, or $0.92 per share, compared with $43.7 million, or $0.84 per share, during the first half of the previous year. Included in this year’s results is a non-cash charge of $22.1 million for amortization of intangibles primarily related to Celera’s acquisition of Paracel.

“We expect that the fundamentals of healthcare delivery and medical practice will be transformed by molecular medicine. We believe that the information and bioinformatics platforms developed by Celera are becoming important tools in this transformation,” noted Tony L. White, Applera’s chief executive officer. “We’re committed to accelerating the development of new therapies and targeted diagnostics.”

“As we expand our information platforms and computational biology skills, we are well-positioned to extend our reach into medical discovery,” said J. Craig Venter, Ph.D., Celera’s president and chief scientific officer. “We’re putting in place a set of capabilities, internally and with a growing list of collaborators, that we believe will give us the opportunity to understand the logic of biology. We intend to use these capabilities to discover and develop innovative new therapies and molecular diagnostic information.”

Celera has recently reported a number of developments in its business, including:

New customer relationships
  • Celera entered into subscription agreements with several academic customers from around the world.
  • In January, Celera announced that Genset S.A. has begun to use Celera’s integrated database products, bioinformatics systems, and other tools in their genomics research.

Expanded business operations
  • In November, Applera Corporation announced the formation of a major initiative in the field of molecular diagnostics and the appointment of Kathy Ordonez, formerly president of Roche Molecular Systems, to lead this initiative.
  • In January, Celera announced that it had launched the updated version of the Celera Discovery System, which provides Celera subscribers comprehensive and convenient desktop access to Celera’s proprietary genome data, research tools, and supercomputing facility via the Internet.
  • In October, Celera announced that it had sequenced 9.3 billion base pairs or 3X of the mouse genome. Through today, Celera has sequenced more than 15.7 billion base pairs for 5X coverage from three strains of the mouse genome that are widely used in scientific research. The Group is now assembling the mouse genome.
  • In November, Celera and LION bioscience AG announced that they had extended their existing collaboration and entered into a strategic alliance to develop and deliver new software tools through the Celera Discovery System.
  • During the second quarter, the Group entered into a collaborative agreement with Diversa Corporation to sequence the genomes and discover the genes of selected, uncultured microorganisms contained in Diversa’s extensive environmental libraries.
  • Earlier this month, Paracel, Inc., a Celera business, introduced GeneMatcher2™, a new generation high-throughput supercomputer, which makes it feasible to apply some of the most sensitive algorithms to industrial-scale genomic problems.
  • Last week, the Department of Energy announced that the Sandia National Lab, Compaq Computer Corporation and Celera had formed a research and development alliance to develop the next generation software and computer hardware solutions specifically designed for the demands of computational biology.
  • Celera announced today that it has signed a collaborative research agreement with Institut de Recherche Pierre Fabre, a French corporation. Using patients enrolled in clinical trials at Pierre Fabre, Celera will explore DNA variations in tubulin genes and certain other genes to better understand the role these genes play in therapeutic benefits and side effects pertaining to certain drugs to treat breast cancer.

A conference call with Applera Corporation and Celera Genomics executives will be held today at 10:00 a.m. (EST) with investors and media to discuss these results. During the call, the Company also will update its outlook for the balance of fiscal 2001. To participate, please phone 212-271-4588 (code “applera”) between 9:45 and 10:00 a.m. (EST). The call will also be webcast live on the Internet, accessible at

Applera Corporation, formerly PE Corporation, comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, intends to become the definitive source of genomic and related medical information. Celera has developed three business units: the On-line Information Business, Discovery Sciences, and Discovery Services, all of which build upon Celera’s generation, integration, and analysis of biological information. Celera intends to enable therapeutic discoveries both through its own application of its scientific capabilities and in partnership with pharmaceutical and biotechnology companies. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA) and proteins in order to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.4 billion for fiscal 2000. Information about Applera Corporation, including reports and other information filed by the Company with the Securities and Exchange Commission, is available on the World Wide Web at, or by telephoning 800.762.6923.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” and “potential,” among others. These forward-looking statements are based on Applera Corporation’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics’ businesses include but are not limited to (1) operating losses to date; (2) a unique and expanding business plan; (3) dependence on the final assembly and annotation of the human genome; (4) uncertainty of revenue growth; (5) unproven use of genomics information to develop products; (6) intense competition in the evolving genomics industry; (7) dependence on customers in and subject to the risks of the pharmaceutical and biotechnology industries; (8) heavy reliance on strategic relationship with the Applied Biosystems Group; (9) potential product liability claims; (10) liabilities related to use of hazardous materials; (11) lengthy sales cycle; (12) dependence on the unique expertise of its scientific and management staff; (13) uncertainty of patent, copyright, and intellectual property protection and the ability to protect trade secrets; (14) dependence on computer hardware, software, and internet applications; (15) access to biological materials; (16) legal, ethical, and social issues affecting demand for products; (17) disruptions caused by rapid growth of the business; (18) government regulation of its products and services; (19) risks of future acquisitions; (20) uncertainty of outcome of stockholder litigation; and (21) other factors that might be described in its filings with the Securities and Exchange Commission.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.